netFormulary Grampian Area NHS
Formulary  
 Search
 Formulary Chapter 5: Infections - Full Chapter
05.03.01  Expand sub section  HIV infection
 note 

Note: The classification ‘hospital use only’ does not prevent supply of medicines by Primary Care, e.g. use of hospital-based prescription (HBP) stationery.

Abacavir
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

RMM Risk Minimisation Materials

 
Link  Risk Minimisation Materials
Link  Risk Minimisation Materials: Patient Alert Card
Link  Drug Safety Update: Abacavir: risk of myocardial infarction - update from epidemiological studies (July 2009)
Link  SMC 174/05: Abacavir for the treatment of HIV-1 infection in adults and adolescents (May 2005)
   
Abacavir/lamivudine
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

RMM Risk Minimisation Materials

 
Link  Risk Minimisation Materials
Link  Risk Minimisation Materials: Patient Alert Card
Link  Drug Safety Update: Abacavir: risk of myocardial infarction—update from epidemiological studies (July 2009)
   
Atazanavir
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
 
Link  SMC 656/10: Atazanavir for the treatment of paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products (Dec 2010)
Link  SMC 520/08: Atazanavir for antiretroviral treatment naïve HIV-1 infected adults (Dec 2008)
Link  SMC 120/04: Atazanavir for the treatment of HIV-1 infected, antiretroviral treatment experienced adults (Sept 2004)
   
bictegravir/emtricitabine/tenofovir alafenamideBlack Triangle (Biktarvy®)
(50mg/200mg/25mg film-coated tablets)
View adult BNF View SPC online
Formulary
Red
 
Link  SMC 2093: Biktarvy® for the treatment of adults infected with human immunodeficiency virus 1 (HIV-1) without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir (Sept. 2018).
   
Darunavir
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
 
Link  Drug Safety Update Articles: Darunavir
Link  SMC advice directory: Darunavir for the treatment of HIV-1 infection
   
Darunavir/cobicistat Black Triangle
(Rezolsta®)
View adult BNF
Formulary
Red
High Cost Medicine
 
Link  Drug Safety Update: Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1 (July 2018)
Link  Drug Safety Update: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects (Dec 2016)
Link  SmPC: darunavir/cobicistat
Link  SMC 1081/15: Darunavir/cobicistat for the treatment of HIV-1 infection in adults aged 18 years or older (Aug 2015).
   
Darunavir/cobicistat/emtricitabine/tenofovir alafenamideBlack Triangle
(Symtuza®)
View adult BNF View childrens BNF
Formulary
Red
 
Link  SmPC: darunavir/cobicistat/emtricitabine/tenofovir alafenamide
Link  Drug Safety Update: Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1 (July 2018)
Link  SMC 1290/18: Symtuza® for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents (aged 12 years and older with body weight at least 40kg) (Jan 2018)
   
Dolutegravir
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
 
Link  Drug Safety Update Articles: Dolutegravir
Link  SMC 1253/17: Dolutegravir for the treatment of HIV-1 infected children aged >6 to 12 years of age (July 2017)
Link  SMC 961/14: Dolutegravir for the treatment of HIV-1 infected adults and adolescents above 12 years of age (May 2014)
   
Dolutegravir/abacavir/lamivudine Black Triangle
(Triumeq®)
View adult BNF View childrens BNF
Formulary
Red
High Cost Medicine

RMM Risk Minimisation Materials

 
Link  Risk Minimisation Materials
Link  SmPC: dolutegravir/abacavir/lamivudine
Link  Drug Safety Update Articles: Triumeq
Link  SMC 1009/14: Dolutegravir/abacavir/lamivudine for the treatment of HIV infected adults and adolescents above 12 years of age weighing at least 40 kg (Dec 2014).
   
Dolutegravir/lamivudineBlack Triangle
(Dovato®)
View adult BNF View childrens BNF
Formulary
Red
High Cost Medicine
 
Link  SmPC: dolutegravir/lamivudine
Link  SMC 2205: Dolutegravir/lamivudine for the treatment of HIV-1 infection in adults and adolescents above 12 years of age weighing at least 40kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine (Sept 2019)
   
dolutegravir/rilvipirineBlack Triangle (Juluca®)
(50mg/25mg film-coated tablets)
View adult BNF
Formulary
Red
 
Link  SmPC: dolutegravir/rilvipirine
Link  SMC 2091: Juluca® for the treatment of HIV-1 infection in adults who are virologically-suppressed on a stable antiretroviral regimen for at least six months no history of virological failure and no resistance to NNRTI or integrase inhibitor (Sept 2018)
   
Efavirenz
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
 
Link  SMC 1125/15: Efavirenz for the treatment of HIV-1 infected children aged 3 months to 3 years and weighing at least 3.5kg (Dec 2015)
   
Efavirenz/emtricitabine/tenofovir disoproxil
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
 
Link  SMC 442/08: Efavirenz/emtricitabine/tenofovir disoproxil for the treatment of HIV-1 infection in adults (April 2008)
   
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamideBlack Triangle
(Genvoya®)
View adult BNF View childrens BNF
Formulary
Red
High Cost Medicine
 
Link  SmPC: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
Link  Drug Safety Update Articles: Elvitegravir
Link  Drug Safety Update: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects (Dec 2016)
Link  SMC 1142/16: Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for the treatment of HIV-1 infection in adults and adolescents (May 2016)
   
Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil
(Stribild® )
View adult BNF
Formulary
Red
High Cost Medicine
 
Link  SmPC: elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil
Link  Drug Safety Update Articles: Elvitegravir
Link  Drug Safety Update: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects (Dec 2016)
Link  SMC 887/13: elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil treatment of HIV-1 infection in adults aged 18 years and over ( Aug 2013).
   
Emtricitabine/rilpivirine/tenofovir disoproxil
(Eviplera®)
View adult BNF
Formulary
Red
High Cost Medicine
 
Link  SmPC: emtricitabine/rilpivirine/tenofovir disoproxil
Link  SMC 951/14: Emtricitabine/tenofovir/rilpiverine for the treatment of HIV-1 infection in adults (April 2014)
Link  SMC 759/12: Emtricitabine/tenofovir/rilpiverine for the treatment of HIV-1 infection in antiretroviral treatment-naive adults (Feb 2012)
   
Emtricitabine/tenofovir alafenamideBlack Triangle
(Descovy®)
View adult BNF View childrens BNF
Formulary
Red

Descovy® 200/25 film-coated tablets
(200mg emtricitabine/25mg tenofovir alafenamide)
Descovy® 200/10 film-coated tablets
(200mg emtricitabine/10mg tenofovir alafenamide)

 
Link  SmPC: emtricitabine/tenofovir alafenamide
Link  SMC 1169/16: Emtricitabine/tenofovir alafenamide for the treatment of HIV-1 infection in adults and adolescents (Aug 2016)
   
Emtricitabine/tenofovir disoproxil
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
 
Link  SMC 1225/17: Emtricitabine/tenofovir disoproxil in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults at high risk (April 2017)
Link  SMC 237/06: Emtricitabine/tenofovir disoproxil for the treatment of HIV-1 infection in adults (Feb 2006)
   
Etravirine
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
 
Link  SMC 901/13: Etravirine for the treatment of HIV-1 infection in antiretroviral treatment-experienced paediatric patients from 6 years to less than 18 years of age (Sept 2013)
Link  SMC 530/09: Etravirine for the treatment of HIV-1 infection in antiretroviral treatment experienced adult patients (Aug 2009)
   
Lamivudine
(150mg, 300mg)
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
   
Lamivudine/zidovudine
View adult BNF View childrens BNF
Formulary
Red
 
Link  SmPC: lamivudine/zidovudine
   
Lopinavir/ritonavir
(Kaletra®)
View adult BNF View childrens BNF
Formulary
Red
High Cost Medicine

Kaletra® 200/50 film-coated tablets (200mg lopinavir/50mg ritonavir)
Kaletra® 400mg/100mg/5mL oral solution (80mg lopinavir/20mg ritonavir/mL)

 
Link  SmPC: lopinavir/ritonavir
Link  Drug Safety Update: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects (Dec 2016)
Link  SMC 1302/18: Lopinavir/ritonavir oral solution for the treatment of human immunodeficiency virus (HIV-1) infected children aged from 14 days to ≤2 years (Feb 2018)
Link  SMC 326/06: Lopinavir/ritonavir for the treatment of HIV-1 infected adults and children above the age of 2 years (Nov 2006).
   
Nevirapine
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
 
Link  SMC 760/12: for the treatment of HIV-1 infected adults, adolescents, and children three years and above and able to swallow tablets (Feb 2012).
   
Raltegravir
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
 
Link  SMC advice directory: Raltegravir for the treatment of HIV-1 infection
   
Rilpiverine/emtrictabine/tenofovir alafenamideBlack Triangle
(Odefsey®)
View adult BNF View childrens BNF
Formulary
Red
 
Link  SmPC: rilpiverine/emtrictabine/tenofovir alafenamide
Link  SMC 1189/16: Rilpiverine/emtrictabine/tenofovir alafenamide for the treatment of HIV-1 infection in adults and adolescents (Oct 2016)
   
Rilpivirine hydrochloride
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
 
Link  SMC 1168/16: Rilpivirine for the treatment of HIV-1 infection in adolescents (Aug 2016)
Link  SMC 758/12: Rilpivirine for the treatment of HIV-1 infection in adults (Feb 2012)
   
Ritonavir
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
 
Link  Drug Safety Update: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects (Dec 2016)
   
Tenofovir disoproxil
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
Link  SMC 900/13: Tenofovir disoproxil for the treatment of HIV 1 infected paediatric and adolescent patients aged 6 to < 12 years (Sept 2013).
Link  Q&A: Switching between liquid and tablet/capsule formulations – Which medicines require extra care?
   
Zidovudine
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
 
   
Lamivudine 100mg
(HIV (off-label))
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red

Restricted Item To be used in the management of HIV for dialysis and severely impaired renal patients.

 
   
 ....
 Non Formulary Items
Abacavir/lamivudine/zidovudine
(Trizivir®)

View adult BNF View childrens BNF
Non Formulary
Black
High Cost Medicine

RMM Risk Minimisation Materials

Link  Risk Minimisation Materials
Link  SmPC: abacavir/lamivudine/zidovudine
 
Atazanavir/cobicistat Black Triangle 
(Evotaz®)

View adult BNF
Non Formulary
Black
High Cost Medicine
Link  SmPC: atazanavir/cobicistat
Link  Drug Safety Update: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects (Dec 2016)
Link  SMC 1098/15: Atazanavir/cobicistat for the treatment of HIV-1 infection in adults and adolescents (Nov 2015)
 
Didanosine

Non Formulary
Black
High Cost Medicine
 
Doravirine Black Triangle  (Pifeltro ®)

View adult BNF
Non Formulary
Black

Doravirine (Pifeltro®) is not recommended for use within NHS Scotland as per SMC 2162.

Link  SmPC: doravirine (Pifeltro®) 100mg film-coated tablets
 
Doravirine/lamivudine/tenofovir disoproxil Black Triangle  (Delstrigo®)

View adult BNF
Non Formulary
Black

Doravirine/lamivudine/tenofovir/disoproxil (Delstrigo®) is not recommended for use within NHS Scotland as per SMC 2163.

Link  SmPC: Delstrigo® 100mg/300mg/245mg film-coated tablets
 
Emtricitabine

View adult BNF View SPC online View childrens BNF
Non Formulary
Black
High Cost Medicine
 
Fosamprenavir

View adult BNF View SPC online View childrens BNF
Non Formulary
Black
High Cost Medicine
 
Indinavir

View adult BNF View childrens BNF
Non Formulary
Black
High Cost Medicine
Link  Summary of Product Characteristics: Indinavir
 
Maraviroc  (Celsentri®)

View adult BNF View SPC online View childrens BNF
Non Formulary
Black
High Cost Medicine

Maraviroc (Celsentri®) is not recommended for use within NHS Scotland as per SMC 458/08 and SMC 1282/17

Link  SMC 1282/17: Maraviroc for treatment-experienced adolescents and children of 2 years and older and weighing at least 10kg infected with only CCR5-tropic HIV-1 detectable (Oct 2017)
Link  SMC 458/08: Maraviroc for treatment-experienced adult patients infected with only CCR5-tropic HIV-1 detectable (Oct 2008)
 
Saquinavir

View adult BNF View SPC online
Non Formulary
Black
High Cost Medicine
 
Tipranavir

Non Formulary
Black
High Cost Medicine
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Homecare
Homecare

Traffic Light Status Information

Status Description

Green

General use.
Treatment may be initiated in either Primary or Secondary Care.  

Amber 1

Available for restricted use under specialist supervision.
Treatment may be initiated in Primary Care on the recommendation of a consultant/specialist.  

Amber 2

Available for restricted use under specialist supervision.
Treatment to be initiated in hospital prior to handover.  

Red

Hospital use only.
Treatment should be supplied by the hospital for the duration of the treatment course.  

Blue

Products shown as blue have multiple indications with varying formulary classifications. For further information see text next to the product.  

Grey

Work is ongoing and will be reviewed at a future meeting  

Non Formulary

Not routinely available in NHS Grampian however if local need is identified:
  • Contact the Pharmacist Team Leader/Principal Pharmacist – Supply (ARI)
  • Treatment is available:
    • From a Specialist Centre in another health board
    • From the National Specialist Service for pulmonary arterial hypertension (Scottish Pulmonary Vascular Unit or similar specialists)
    • Through the National Services Scotland:
      • Ultra-Orphan Medicines Risk Share Scheme
      • Inherited Metabolic Disorders Risk Share Scheme
    • For SMC recommended medicines/indications where local clinical experts do not wish to add to the formulary at this time
  

Black

Not routinely available in NHS Grampian.
Includes medicines/indications that:
  • Are not recommended for use within NHS Grampian
  • Are not recommended for use within NHS Scotland
  • Have not been considered by SMC or NHSG Formulary Group
  • Are not recommended for use at present due to limited clinical and/or cost effective data
  • There is a local preference for alternative medicines
  

netFormulary